Aducanumab has been a hot topic in the field of dementia and Alzheimer's disease. Aducanumab, also known as Aduhelm, is a new Alzheimer's drug for people with Alzheimer's disease in their early stages with mild cognitive impairment. With so many questions, it helps to have answers from experts like Dr. Jason Karlawish, Neurologist and Co-Director of the Penn Memory Center.In this episode, Dr. Karlawish and I discucss:Reasons that Dr. Karlawish is a "reluctant prescriber" of AducanumabThe risks and benefits of Aducanumab for Alzheimer's DiseaseHow the FDA made the decision to approve Aducanumab for useThe answer to the question: "is some hope is better than no hope?" (related to the use of Aducanumab for Alzheimers.)The effects of the COVID-19 virus on brain health (i.e., risk for dementia)The difference between FDA approval for Aducanumab versus COVID-19 vaccineClick here to visit the show notes page for all the resources mentioned in today's episode:Older Adult / Family? Download the Memory Loss & Mental Health GuideProfessional? Grab the Mental Health Professional’s Guide to Working with Older AdultsHelp others find this show by subscribing and leaving a review wherever you listen to the podcast, or here on i-tunes.--DISCLAIMER: The material on this site is for informational and educational purposes only. Any comments Dr. Koepp may make on the TV Show, blog, or in response to an individual’s story or comments should not be construed as establishing a psychologist-patient relationship between Dr. Koepp and the individual. None of Dr. Koepp's show, website, social media, comments, or group information should be considered a substitute for individualized medical or mental health assessment, diagnosis, or treatment. Dr. Koepp is only representing herself in her TV Show, blogs, and on her website.